IP case - Atorvastain
Strategies for early generic launch - Atorvastatin
The major constraining patent for Atorvastaitn is EP-00247633. Patentee is Warner-Lambert company. Priority date is 30 May 1986. SPC for EP-00247633 will expire in Nov. 2011 in number of EU countries. However, in Slovenia, Czech R., Bulgaria, Hungary, Poland and Slovakia there is no national patents with link to EP-00247633 as primary patent.
Read more...
Evergreening
Evergreening through Patent Strategies
One form of evergreening occurs when the originator manufacturer “stockpiles” patent protection by obtaining separate 20-year patents on multiple attributes of a single product. But many other evergreening strategies exist ...
Information provided by European Generic Association.
Read more...
IP Case - Sildenafil
Strategies for successful generic launch in European Union - Sildenafil case
The experts of Framvita.Net have made an brief analysis of current status of intellectual property and generic products about sildenafil. This article may help you in planning of successful launch of generic sildenafil in European Union.
Read more...
Patent Expiry Dates
How to Calculate Standard Patent Expiry Dates and Data Exclusivity in Key Territories
Use this handy guide to navigate the calculation of patent expiry dates in US, Canada, Germany, Spain, France, United Kingdom and Australia, and also data exclusivity in the US, Canada, Europe and Australia.
Read more...
Rosiglitazone maleate
Avandia® Patents Afford Protection Against Generic Competition
Generic pharmaceutical manufacturers should proceed with caution when developing generic versions of Avandia®, (Rosiglitazone maleate), according to experts at GenericsWeb.
Read more...
Zyllt (Clopidogrel)
Motion for temporary injunction prohibiting marketing of Zyllt (Clopidogrel)
The plaintiff, Sanofi Pharma BristolMyers Squibb SNC, Paris, France,
has filed a motion for temporary injunction at the District Court of
Warsaw, Poland, against Krka Polska Sp. z o.o., Warsaw, Poland (under
100% ownership by Krka, d. d., Novo mesto, Slovenia), prohibiting the
marketing of Zyllt (clopidogrel) in Poland due to alleged disloyal competition.
Read more...
SEMISOLID DOSAGE FORM
Novel Approches about Semisolid Dosage Forms
The new access in semisolid dosage forms by adding or applying some new approaches to improve them from bioavailability, efficacy, drug dosing cost etc and also techniques which may be launched recently, but not widely used.
Read more...
Vardenafil
Vardenafil (Levitra®) - Opportunity for Proactive Generic Companies?
The recently released GenericsWeb Pipeline Developer patent report for Vardenafil (Levitra®) highlights the importance of high quality patent information when considering development of generic equivalents in the early stages of a product’s life cycle.
Read more...
Vardenafil
Vardenafil (Levitra®) - Opportunity for Proactive Generic Companies?
The recently released GenericsWeb Pipeline Developer patent report for Vardenafil (Levitra®) highlights the importance of high quality patent information when considering development of generic equivalents in the early stages of a product’s life cycle.
Read more...
